Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lupin Ltd Capital/Financing Update 2023

Sep 22, 2023

61031_rns_2023-09-22_e77ae358-23aa-46c9-b129-d4877c98a5de.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

September 22, 2023

==> picture [84 x 99] intentionally omitted <==

BSE Limited

Department of Corporate Services, P. J. Towers, Dalal Street, Mumbai Samachar Marg, MUMBAI - 400 001.

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex, Bandra (East),

MUMBAI - 400 051.

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’).

Dear Sir/Madam,

In compliance with Regulation 30 read with Schedule III of the Listing Regulations and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, we are pleased to inform you that the Company has signed an agreement with A. Menarini India Pvt. Ltd. and A. Menarini Asia-Pacific Holdings Pte. Ltd. (collectively ‘Menarini’), for acquiring five legacy brands in strategic therapy areas viz. Gastroenterology, Urology and Anti-infectives, along with the associated trademark rights, particulars of which are as under: -

- Name of the Acquirer Lupin Limited

Name of the Acquirer- Lupin Limited
a) name of the target entity, details in brief such as size, turnover
etc.;
Menarini is an Italian pharma
group.
The
brands
Piclin
(Picosulphate
Sodium),
Menoctyl
(Otilonium
Bromide),
Sucramal
O
(Sucralfate + Oxetacaine),
Pyridium
(Phenazopyridine)
and Distaclor (Cefaclor) are
being acquired.
Turnover of the said brands
for the year ended March 31,
2023 was about INR 322
million.
b) whether the acquisition would fall within related party
transaction(s) and whether the promoter/promoter group/group
companies have any interest in the entity being acquired? If yes,
nature of interest and details thereof and whether the same is
done at “arms-length”;
No.
c) industry to which the entity being acquired belongs; Pharmaceuticals.

…1.

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

-2-

==> picture [84 x 99] intentionally omitted <==

d) objects and impact of acquisition (including but not limited to,
disclosure of reasons for acquisition of target entity, if its business
is outside the main line of business of the listed entity);
The brands being acquired
are in line with the business of
the Company.
The acquisition aligns well
with the Company’s strategic
goal to broaden its presence
in the Indian market. By
offering
a
comprehensive
range of products, the aim is
to deliver even greater value
to
stakeholders
and
the
communities the Company
serves.
e) brief details of any governmental or regulatory approvals
required for the acquisition;
N.A.
f) indicative time period for completion of the acquisition; Acquisitions stand completed.
g) consideration - whether cash consideration or share swap or any
other form and details of the same;
Cash consideration.
h) cost of acquisition and/or the price at which the shares are
acquired;
The consideration is about
INR 1010 million.
i) percentage of shareholding/control acquired and/or number of
shares acquired;
The acquisition is of brands
along with the associated
trademark rights and not of
any
unit
or
division
of
Menarini.
j) brief background about the entity acquired in terms of
products/line of business acquired, date of incorporation, history
of last 3 years turnover, country in which the acquired entity has
presence and any other significant information (in brief);
Menarini group, is a leading
international
pharma
and
diagnostics company, with
presence
in
over
140
countries. It is focused on
therapeutic
areas
viz.
cardiology,
oncology,
pneumology,
gastroenterology,
infectious
diseases,
diabetology,
inflammation and analgesia.
Revenues
from
target
portfolio products in the last 3
years were: -
FY21 - INR 227 million;
FY22 - INR 260 million; and
FY23 - INR 322 million.

…2.

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

-3-

==> picture [84 x 99] intentionally omitted <==

As the acquisition is of brands, we will not be submitting this disclosure in XBRL form.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

Rajvardhan Vishnu Satam

Digitally signed by Rajvardhan Vishnu Satam DN: c=IN, st=Maharashtra, 2.5.4.20=c19d8ef961d9fa59e973a093a4d3924b2532eb2f496ea7e2abcf74 700f5375b7, postalCode=400104, street=2404,SEJAL TOWER,SEJAL PARK,LINK ROAD,GOREGAON WEST,Mumbai,Motilal Nagar,Borivali,Mumbai Suburban, pseudonym=9a4b7cd219ea516ad56e6d651dcbbe5b, title=0191, serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f726cdb67a2 ff09c4242771b2a, o=Personal, cn=Rajvardhan Vishnu Satam Date: 2023.09.22 13:12:43 +05'30'

R. V. SATAM COMPANY SECRETARY (ACS -11973)

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com